Page results
-
This page provides information for patients who are due to be admitted to hospital for bowel surgery.
-
Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. In some cases, the tumour spreads into the surrounding areas.
-
The children's FGM service is a dedicated monthly multidisciplinary clinic for girls under 18 years old who have had, are suspected to have had, or who may be at risk of having, FGM.
-
The Secretary of State for Health and Social Care, The Rt. Hon. Sajid Javid MP visited the National Hospital for Neurology and Neurosurgery (NHNN), earlier this week (Wednesday 4 May 2022).
-
A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at University College London Hospitals (UCLH) NHS Foundation Trust.
-
Medtronic are discontinuing the MiniMed™ Mio™ Infusion sets. If you are currently using MiniMed™ Mio™ infusion sets, you will need to change to an alternative infusion set before 31 March 2023. After this date, MiniMed™ Mio™ infusion sets will no longer be available.
-
UCLH-led research paper outlines mechanism behind rare cases of blood clots and low platelets after vaccination
-
This page provides information about food and drink which may affect your ileostomy output.
-
As an organisation, UCLH needs to minimise the environmental impact of our buildings and the energy they use and maximise our use of any technology available to support these changes. This page outlines our progress to date.
-
A new study at UCLH and UCL aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile of their tumour.
File results
-
FOI/2022/0207 - Patient treatment with Nivolumab
-
FOI/2022/0209 - Patient tracking list or waiting lists
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services
-
FOI/2022/0226 - Treatments for Haemophilia A